Circassia Pharmaceuticals (CIR) Sets New 52-Week Low at $24.90

Circassia Pharmaceuticals PLC (LON:CIR) hit a new 52-week low on Tuesday . The company traded as low as GBX 24.90 ($0.33) and last traded at GBX 26.10 ($0.34), with a volume of 670470 shares trading hands. The stock had previously closed at GBX 26.55 ($0.35).

CIR has been the topic of a number of recent analyst reports. Numis Securities restated a “buy” rating and set a GBX 110 ($1.44) price objective on shares of Circassia Pharmaceuticals in a research note on Monday, April 1st. Royal Bank of Canada dropped their price target on shares of Circassia Pharmaceuticals from GBX 81 ($1.06) to GBX 65 ($0.85) and set a “sector performer” rating on the stock in a research report on Thursday, January 24th. Finally, Peel Hunt reiterated an “under review” rating on shares of Circassia Pharmaceuticals in a research report on Thursday, January 24th.

The stock has a market capitalization of $97.73 million and a P/E ratio of -0.77.

TRADEMARK VIOLATION NOTICE: “Circassia Pharmaceuticals (CIR) Sets New 52-Week Low at $24.90” was reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.thelincolnianonline.com/2019/05/21/circassia-pharmaceuticals-cir-sets-new-52-week-low-at-24-90.html.

Circassia Pharmaceuticals Company Profile (LON:CIR)

Circassia Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of respiratory diseases. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; and Tudorza for the treatment of chronic obstructive pulmonary disease (COPD).

See Also: Economic Reports

Receive News & Ratings for Circassia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.